• 1
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342: 3149.
  • 2
    Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356: 3239.
  • 3
    Perucca E. Pharmacologic advantages of antiepileptic drug monotherapy. Epilepsia 1997;38(suppl 5):S68.
  • 4
    Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on Seizure 2000;9: 4648.
  • 5
    Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition Seizure 2002;11: 7784.
  • 6
    Leach JP. Antiepileptic drugs: safety in numbers Seizure 2000;9: 1708.
  • 7
    Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42: 125560.
  • 8
    Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 2000;41: 136474.
  • 9
    Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002;11: 34951.
  • 10
    Deckers CLP. Overtreatment in adults with epilepsy. Epilepsy Res 2002;52: 4352.
  • 11
    Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992;13: 10712.
  • 12
    Macdonald RL, Greenfield LJ. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997;10: 1218.
  • 13
    Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in J Child Neurol 1997;12(suppl 1):S29.
  • 14
    Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug, II: neurochemical studies on the mechanism of action. Epilepsia 1986;27: 4907.
  • 15
    Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy Epilepsia 1997;38: 95965.
  • 16
    Dalby NO, Nielsen EB. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res 1997;28: 6372.
  • 17
    Miller AA, Wheatley P, Sawyer DA, et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug, I: anticonvulsant profile in mice and rats. Epilepsia 1986;27: 4839.
  • 18
    Hosford DA, Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38: 40814.
  • 19
    Murphy K, Delanty N. Primary generalized epilepsies. Curr Treat Options Neurol 2000;2: 52741.
  • 20
    Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000;41: 88794.
  • 21
    Binnie CD, Debets RM, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989;4: 2229.
  • 22
    Loiseau P, Yuen AW, Duche B, et al. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7: 13645.
  • 23
    Buchanan N. Lamotrigine in the treatment of absence seizures. Acta Neurol Scand 1995;92: 348.
  • 24
    Warner T, Patsalos PN, Prevett M, et al. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11: 14750.
  • 25
    Borowicz KK, Gasior M, Kocki T, et al. Anticonvulsant activity, adverse effects and plasma levels of conventional antiepileptic drugs at different times after single administration. Pol J Pharmacol 1997;49: 69.
  • 26
    Luszczki JJ, Borowicz KK, Swiader M, et al. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44: 48999.
  • 27
    Boissier JR, Tardy J, Diverres JC. Une nouvelle methode simple pour explorer l′action “tranquilisante”: le test de la cheminee. Med Exp (Basel) 1960;3: 814.
  • 28
    Venault P, Chapouthier G, Carvalho LP, et al. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 1986;321: 8646.
  • 29
    Tallarida RJ, Stone DJ, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sci 1997;61: PL41725.
  • 30
    Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96: 99113.
  • 31
    Tallarida RJ, Murray RB. Manual of pharmacologic calculations with computer programs. 2nd ed. New York : Springer-Verlag, 1987.
  • 32
    Borowicz KK, Swiader M, Luszczki J, et al. Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis. Epilepsia 2002;43: 95663.
  • 33
    Löscher W, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs, IV: protective indices. Epilepsy Res 1991;9: 110.
  • 34
    Czuczwar SJ, Patsalos NP. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs 2001;15: 33950.
  • 35
    Braga MF, Aroniadou-Anderjaska V, Post RM, et al. Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. Neuropharmacology 2002;42: 5229.
  • 36
    Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39: 213946.
  • 37
    Waldmeier PC, Baumann PA, Wicki P, et al. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45: 190713.
  • 38
    Wang SJ, Huang CC, Hsu KS, et al. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 1996;7: 303740.
  • 39
    Löscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998;342: 113.
  • 40
    Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42: 22386.
  • 41
    Czuczwar SJ, Gasior M, Janusz W, et al. Influence of different methylxanthines on the anticonvulsant action of common antiepileptic drugs in mice. Epilepsia 1990;31: 31823.
  • 42
    Lohse MJ, Klotz KN, Jakobs KH, et al. Barbiturates are selective antagonists at A1 adenosine receptors. J Neurochem 1985;45: 176170.
  • 43
    Morris JC, Dodson EW, Hatlelid MJ, et al. Phenytoin and carbamazepine, alone and in combination: anticonvulsant and neurotoxic effects. Neurology 1987;37: 11118.
  • 44
    Bourgeois BFD, Wad N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice. J Pharmacol Exp Ther 1984;231: 4115.
  • 45
    Bourgeois BFD. Reducing overtreatment. Epilepsy Res 2002;52: 5360.
  • 46
    Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57: 141621.
  • 47
    Leppik IE. AED doses: from animals to humans. In: FrenchJ, LeppikI, DichterMA, eds. Antiepileptic drug development: advances in neurology. Philadelphia : Lippincott-Raven, 1998: 76: 8993.
  • 48
    Löscher W, Wauquier A. Use of animal models in developing guiding principles for polypharmacy in epilepsy. Epilepsy Res Suppl 1996;11: 615.
  • 49
    De Romanis F, Sopranzi N. Lamotrigine: monotherapy in refractory epilepsy. Clin Ter 1997;148: 1538.
  • 50
    De Romanis F, Sopranzi N. Lamotrigine in the therapy of resistant epilepsy. Clin Ter 1999;150: 27982.
  • 51
    Schmidt D, Elger C, Holmes GL. Pharmacological overtreatment in epilepsy: mechanisms and management. Epilepsy Res 2002;52: 314.
  • 52
    Perucca E. Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res 2002;52: 2533.
  • 53
    Holmes GL. Overtreatment in children with epilepsy. Epilepsy Res 2002;52: 3542.
  • 54
    Deckers CLP. Overtreatment in adults with epilepsy. Epilepsy Res 2002;52: 4352.
  • 55
    Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res 2002;52: 619.
  • 56
    Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction Epilepsia 1998;39: 1837.
  • 57
    Jozwiak S, Terczynski A. Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure 2000;9: 48692.
  • 58
    Benetello P, Furlanut M, Baraldo M, et al. Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. Eur Neurol 2002;48: 2003.
  • 59
    Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26: 42332.
  • 60
    Barrett C, Richens A. Epilepsy and pregnancy: report of an Epilepsy Research Foundation Workshop. Epilepsy Res 2003;52: 14787.
  • 61
    Cadart M, Marchand S, Pariat C, et al. Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharm Res 2002;19: 20914.
  • 62
    Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine with sodium valproate. Lancet 1993;341: 445.
  • 63
    Pisani F, Di Pierri R, Perruca E, et al. Interaction of lamotrigine with sodium valproate. Lancet 1993;341: 1224.
  • 64
    Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998;351: 9589.